NO944931L - Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet - Google Patents

Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet

Info

Publication number
NO944931L
NO944931L NO944931A NO944931A NO944931L NO 944931 L NO944931 L NO 944931L NO 944931 A NO944931 A NO 944931A NO 944931 A NO944931 A NO 944931A NO 944931 L NO944931 L NO 944931L
Authority
NO
Norway
Prior art keywords
phenyl
sexual maturity
aroylbenzothiophenes
early sexual
inhibiting early
Prior art date
Application number
NO944931A
Other languages
English (en)
Other versions
NO944931D0 (no
Inventor
Jeffrey Alan Dodge
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944931D0 publication Critical patent/NO944931D0/no
Publication of NO944931L publication Critical patent/NO944931L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Anvendelse av en effektiv mengde av en forbindelse som har formelen:. hvor Rog ruavhengig er hydrogen -CHo, alkyl).eller. hvor Ar er eventuelt substituert fenyl;. Rer valgt fra gruppen bestående av pyrrolldino, heksametylenlmlno, og plperldlno; eller et farmasøytisk akseptabelt salt eller solvat derav, for lnhlbering av tidlig seksuell modenhet ved administrasjon til et menneske av en effektiv mengde av nevnte forbindelse.
NO944931A 1993-12-21 1994-12-19 Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet NO944931L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,393 US5451590A (en) 1993-12-21 1993-12-21 Methods of inhibiting sexual precocity

Publications (2)

Publication Number Publication Date
NO944931D0 NO944931D0 (no) 1994-12-19
NO944931L true NO944931L (no) 1995-06-22

Family

ID=22623576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944931A NO944931L (no) 1993-12-21 1994-12-19 Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet

Country Status (14)

Country Link
US (2) US5451590A (no)
EP (1) EP0659420A1 (no)
JP (1) JPH07215857A (no)
KR (1) KR950016734A (no)
CN (1) CN1108099A (no)
AU (1) AU8155294A (no)
CA (1) CA2138507A1 (no)
CZ (1) CZ321794A3 (no)
HU (1) HUT71340A (no)
IL (1) IL112051A0 (no)
NO (1) NO944931L (no)
NZ (1) NZ270179A (no)
RU (1) RU94045156A (no)
ZA (1) ZA9410075B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US7209221B2 (en) * 1994-05-23 2007-04-24 Automotive Technologies International, Inc. Method for obtaining and displaying information about objects in a vehicular blind spot
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
US7852462B2 (en) * 2000-05-08 2010-12-14 Automotive Technologies International, Inc. Vehicular component control methods based on blind spot monitoring
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (no) * 1962-09-13
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
US5552417A (en) 1996-09-03
CA2138507A1 (en) 1995-06-22
JPH07215857A (ja) 1995-08-15
CN1108099A (zh) 1995-09-13
US5451590A (en) 1995-09-19
HUT71340A (en) 1995-11-28
HU9403669D0 (en) 1995-02-28
CZ321794A3 (en) 1995-09-13
NO944931D0 (no) 1994-12-19
EP0659420A1 (en) 1995-06-28
NZ270179A (en) 1996-08-27
KR950016734A (ko) 1995-07-20
AU8155294A (en) 1995-06-29
ZA9410075B (en) 1996-06-19
IL112051A0 (en) 1995-03-15
RU94045156A (ru) 1996-10-20

Similar Documents

Publication Publication Date Title
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO944934L (no) Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom
ATE216582T1 (de) Hemmung uteriner fibrose
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
DK0659417T3 (da) Fremgangsmåder til inhibering af dysfunktionel blødning fra livmoderen
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
KR950010887A (ko) 연골 퇴화 억제 방법
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944917D0 (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme
KR950016734A (ko) 성적 조숙증의 억제방법
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO975580L (no) Fremgangsmåte for å inhibere melanom
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
NO933435L (no) Piperidinderivater, deres fremstilling og anvendelse
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
DE69421694D1 (en) Interleukin-1 inhibitor
NO944577L (no) Hemming av effekten av amyloidogene proteiner
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser